Safety
ADVERSE EVENTS, ADVERSE EVENT, CORONAVIRUS
Treatment-emergent adverse events (TEAEs) were reported in 41/67 (61.2%) of patients treated with pegozafermin versus 9/18 (50%) on placebo (Table Summary of safety and tolerabilityCOVID-19, coronavirus disease-19; TEAE, treatment-emergent adverse event; PGZ, pegozafermin.Safety analysis set is defined as all participants who received at least one dose of investigational product. The safety analysis set is summarized based on planned treatment. Four participants randomized to receive 9 mg QW received 18 mg QW throughout the treatment; these four participants were categorized in the actual treatment group of 18 mg QW in safety analysis. Three participants randomized to receive 27 mg QW received 36 mg QW throughout the treatment; these three participants were categorized in the planned treatment group of 27 mg QW as it was the highest QW dose in the study.